DCGI Approves Zytorvi for Cancer: Toripalimab Approval 2026

DCGI approves Zytorvi for cancer in India in 2026. Learn about toripalimab, advanced esophageal cancer treatment, the JUPITER-06 trial and key exam facts.

Introduction: New Immunotherapy Option for Cancer Patients

On 21 October 2026, Dr. Reddy’s Laboratories announced that it had received approval from India’s drug regulatory authorities for Zytorvi, a medicine containing toripalimab, for the treatment of advanced esophageal squamous cell carcinoma (ESCC). The drug is approved for use alongside two chemotherapy medicines, cisplatin and paclitaxel, as a first-line treatment for eligible adult patients. The development expands the treatment options available for patients with an aggressive form of esophageal cancer.

What Is Zytorvi and How Does It Work?

Zytorvi is the brand name for toripalimab, a humanised monoclonal antibody used in cancer immunotherapy. It targets a protein called programmed cell death protein 1 (PD-1), which is found on immune cells. Cancer cells can exploit immune-regulatory pathways to avoid being attacked by the body’s defence system. By blocking the interaction between PD-1 and its ligands, PD-L1 and PD-L2, toripalimab helps restore T-cell activity against cancer cells. It is administered as part of a specialist-supervised treatment plan rather than as a general-purpose medicine.

Details of the DCGI Approval

The approved treatment combines toripalimab with cisplatin and paclitaxel. It is intended for adults with unresectable advanced, recurrent or metastatic ESCC. Unresectable cancer is cancer that cannot be removed completely through surgery, while recurrent cancer returns after treatment and metastatic cancer spreads to other parts of the body. The term first-line treatment refers to the initial treatment used for a particular disease stage or clinical situation. The approval therefore gives eligible patients and oncologists another option at the beginning of treatment for advanced ESCC.

Why Is the Approval Significant for India?

Esophageal cancer remains a major public health concern in India. According to figures cited in reporting on the approval, the disease accounted for approximately 8.1% of cancer-related deaths in India in 2024. Esophageal squamous cell carcinoma represents around 80% of esophageal cancer cases in the country. These figures highlight the importance of expanding access to effective treatment approaches and strengthening cancer-care services. The new indication is particularly relevant because it addresses a common type of esophageal cancer that can be difficult to treat when it has reached an advanced stage.

Clinical Evidence Supporting the Approval

The approval was supported by findings from the Phase III JUPITER-06 clinical trial. As reported by the company, the combination of toripalimab with chemotherapy reduced the risk of disease progression or death by 42% compared with chemotherapy alone. Median overall survival was reported as 17.7 months in the toripalimab combination group, compared with 12.9 months in the chemotherapy-only group. These results provide clinical evidence supporting the use of immunotherapy alongside chemotherapy for eligible patients. However, individual outcomes vary, and treatment decisions must be made by qualified oncology specialists after considering the patient’s condition and potential risks.

Dr. Reddy’s Laboratories and the Development of Toripalimab

Dr. Reddy’s Laboratories is an Indian pharmaceutical company involved in the development, manufacture and marketing of medicines. In 2023, the company entered into a licensing and commercialisation agreement with Shanghai Junshi Biosciences for toripalimab across 21 countries. The medicine had already received approval in India for certain forms of nasopharyngeal carcinoma, a cancer affecting the upper part of the throat behind the nose. The approval for ESCC represents a second indication for Zytorvi in India and broadens its potential role in cancer treatment.

Role of Drug Regulation in India

The Drugs Controller General of India (DCGI) operates within the Central Drugs Standard Control Organisation (CDSCO), which functions under the Ministry of Health and Family Welfare. CDSCO is responsible for important regulatory functions involving drugs and clinical trials at the national level. Regulatory review helps assess whether medicines meet applicable standards of safety, quality and efficacy for their proposed uses. The approval of an additional indication means that a medicine already authorised for one condition has received permission for another specified use. This development is relevant to government examinations covering health policy, biotechnology, pharmaceutical regulation and public administration.

Important Medical Terms for Competitive Exams

Candidates should understand the difference between immunotherapy and chemotherapy. Chemotherapy uses medicines that damage or kill cancer cells, while immunotherapy helps the immune system recognise or attack cancer. A monoclonal antibody is a laboratory-produced antibody designed to recognise a specific target. PD-1 is an immune checkpoint protein that helps regulate immune responses. ESCC is a subtype of esophageal cancer arising from squamous cells lining the esophagus. Understanding these concepts can help candidates answer questions in general science, biology, health-related current affairs and medical developments.

B) Why This News Is Important

1. Importance for Public Health in India

The approval of Zytorvi for advanced esophageal squamous cell carcinoma is important because esophageal cancer contributes significantly to India’s cancer burden. Expanding treatment options can help oncologists consider immunotherapy in addition to conventional chemotherapy for eligible patients. The development also highlights the importance of improving access to specialised cancer care and strengthening awareness of cancer prevention and early diagnosis.

2. Advancement in Cancer Immunotherapy

Toripalimab is an example of immunotherapy based on immune checkpoint inhibition. Its ability to block PD-1 helps immune cells recognise and attack cancer cells more effectively. The clinical trial results reported for the combination treatment demonstrate the potential benefits of integrating immunotherapy with chemotherapy in advanced cancer management.

3. Relevance for Government Examinations

This development is relevant to current affairs, general science, biotechnology and public health topics in examinations such as UPSC, State PSC, SSC, banking and defence recruitment tests. Candidates should remember the drug’s brand name, generic name, target disease, combination medicines and the role of India’s drug regulator.

4. Significance for the Pharmaceutical Sector

The approval expands the Indian commercial use of toripalimab and illustrates how licensing agreements can support the introduction of innovative medicines. It also highlights the role of domestic pharmaceutical companies in making specialised cancer treatments available in India.

C) Historical Context: Development of Cancer Immunotherapy

Evolution of Cancer Treatment

Cancer treatment has traditionally relied on surgery, radiation therapy and chemotherapy. Although these approaches remain essential, advances in molecular biology and immunology have enabled the development of targeted therapies and immunotherapies. These newer approaches seek to interfere with specific cancer-related mechanisms or strengthen the body’s immune response against malignant cells.

Emergence of PD-1 Inhibitors

PD-1 inhibitors are an important class of immune checkpoint inhibitors. They block signals that cancer cells can exploit to reduce immune activity. Over the past decade, medicines targeting immune checkpoints have become established treatment options for several cancers, depending on the disease type, stage and clinical circumstances. Toripalimab belongs to this class and was developed by Shanghai Junshi Biosciences.

Toripalimab’s Earlier Approval in India

In 2024, toripalimab became available in India under the brand name Zytorvi for specified indications involving recurrent or metastatic nasopharyngeal carcinoma. Dr. Reddy’s Laboratories had entered into a licensing and commercialisation agreement with Junshi Biosciences in 2023. The October 2026 approval for advanced ESCC expands the medicine’s approved use in India.

Regulatory Review and Clinical Trials

The new indication followed clinical evidence and regulatory review. India’s Subject Expert Committee on Oncology had considered the proposal in earlier meetings, including discussions about the evidence required for further consideration. The Phase III JUPITER-06 trial subsequently provided important evidence supporting the combination of toripalimab and chemotherapy. This process illustrates how clinical research and regulatory assessment contribute to decisions about new uses for medicines.

D) Key Takeaways from Zytorvi Approval for Esophageal Cancer

Frequently Asked Questions (FAQs)

FAQ 1. What is Zytorvi?

Zytorvi is the brand name of toripalimab, an immunotherapy medicine used to treat certain cancers. It is a monoclonal antibody that targets the PD-1 immune checkpoint protein.

FAQ 2. Who approved Zytorvi for advanced esophageal cancer in India?

The Drugs Controller General of India (DCGI), under the Central Drugs Standard Control Organisation (CDSCO), approved the medicine’s additional indication in October 2026.

FAQ 3. What is the full form of ESCC?

ESCC stands for Esophageal Squamous Cell Carcinoma, a type of cancer that develops in the squamous cells lining the esophagus, the tube that carries food from the throat to the stomach.

FAQ 4. Which medicines are combined with toripalimab for this treatment?

Toripalimab is used in combination with two chemotherapy medicines: cisplatin and paclitaxel.

FAQ 5. What is the mechanism of action of toripalimab?

Toripalimab blocks the PD-1 protein from interacting with its ligands, PD-L1 and PD-L2. This helps restore T-cell activity and supports the immune system’s ability to attack cancer cells.

FAQ 6. What is first-line cancer treatment?

First-line treatment is the initial treatment recommended for a particular disease stage or clinical situation. In this case, the approved combination is intended for eligible adults with unresectable advanced, recurrent or metastatic ESCC.

FAQ 7. Which clinical trial supported the approval?

The approval was supported by findings from the Phase III JUPITER-06 clinical trial. The reported results showed a reduction in the risk of disease progression or death when toripalimab was combined with chemotherapy.

FAQ 8. What were the median overall survival results in the JUPITER-06 trial?

Median overall survival was reported as 17.7 months for patients receiving toripalimab with chemotherapy, compared with 12.9 months for those receiving chemotherapy alone. These are trial-level results and do not predict an individual patient’s outcome.

FAQ 9. What is the role of the DCGI in India?

The DCGI is responsible for important national drug-regulatory functions within CDSCO, including regulatory oversight related to drug approvals and clinical trials.

FAQ 10. Which company markets Zytorvi in India?

Dr. Reddy’s Laboratories holds commercialisation rights for toripalimab in India under an agreement with Shanghai Junshi Biosciences. The agreement, signed in 2023, covers 21 countries.

FAQ 11. What was Zytorvi’s earlier approved indication in India?

Before the October 2026 approval for ESCC, Zytorvi was approved in India for specified cases of recurrent or metastatic nasopharyngeal carcinoma. The ESCC approval is its second approved indication in the country.

Some Important Current Affairs Links